Optinose Inc (OPTN) Return on Equity ROE from the first quarter 2025 to first quarter 2024 and annually, average high and low, overall ranking from Mar 31 2025 to Mar 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Optinose Inc   (NASDAQ: OPTN)

Optinose Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Optinose Inc in the first quarter 2025?
Due to the lack of equity, it was not possible to calculate Optinose Inc 's return on equity (ROE) in its first quarter 2025

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Mar 31 2025)
I. Quarter		 (Dec 31 2024)
IV. Quarter		 (Sep 30 2024)
III. Quarter		 (Jun 30 2024)
II. Quarter		 (Mar 31 2024)
I. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -30 -22 -31 -41 -31
Return On Equity (TTM) - - - - -
OPTN's Total Ranking # # # # #
Equity (TTM) in Millions -61 -40 -41 -43 -99
Seq. Equity Change - - - - -
Seq. Net Income Change - - - - -

Back to OPTN Management Effectiveness >> OPTN's 5 Years Annual ROE >> Compare OPTN ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





OPTN Annual Return On Equity (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020
Total Equity in Millions -40 -87 -57 -22 7
Y / Y Equity Change - - - - -88.98 %
Net Income in Millions -22 -35 -75 -82 -100
Y / Y Net Income Change - - - - -
Return On Equity - - - - -1470.02 %

Back to OPTN Management Effectiveness >> OPTN's 5 Years Annual ROE >> Compare OPTN ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
OPTN's' Return on Equity at Yahoo Finance
OPTN's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for OPTN's Competitors
Subscribers only: Roe for Optinose Inc 's Suppliers
Subscribers only: Return On Equity for OPTN's Customers




Companies with similar Return On Equity at Mar 31 2025, within Healthcare Sector ROE
Stablecoin Development Corporation  163.62 %
Tao Synergies Inc   140.18 %
Halozyme Therapeutics Inc   122.24 %
Avalo Therapeutics Inc   111.00 %
Earth Science Tech Inc   104.38 %
3m Company  102.39 %
Abbvie Inc   94.89 %
Amgen Inc   92.94 %
Medinotec Inc   77.00 %
Eli Lilly And Company  76.50 %
Synlogic Inc   73.65 %
Adma Biologics Inc   72.39 %
Longduoduo Co Ltd  71.83 %
Nrc Health  71.33 %
Exelixis Inc   67.57 %
Dariohealth Corp   65.81 %
Pharmacyte Biotech Inc   62.23 %
Idexx Laboratories Inc  57.35 %
Medpace Holdings Inc   54.36 %
Agios Pharmaceuticals Inc   50.31 %
Zoetis Inc   50.22 %
Puma Biotechnology Inc   49.30 %
Edwards Lifesciences Corporation  44.69 %
Sbc Medical Group Holdings Incorporated  44.32 %
Tenet Healthcare Corp  42.42 %
Agilent Technologies inc   41.87 %
Waters Corporation  38.48 %
Merck and Co Inc   38.15 %
Hims and Hers Health Inc   35.97 %
Acadia Pharmaceuticals Inc   35.32 %

Date modified: 2026-09-26T07:37:49+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.